{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T10:19:27Z","timestamp":1763201967815},"reference-count":25,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2016,4,20]],"date-time":"2016-04-20T00:00:00Z","timestamp":1461110400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J of Clinical Hypertension"],"published-print":{"date-parts":[[2016,10]]},"abstract":"<jats:p>The authors sought to retrospectively analyze the real\u2010world evidence on aliskiren in diabetic patients with or without concomitant renin\u2010angiotensin system (<jats:styled-content style=\"fixed-case\">RAS<\/jats:styled-content>) blocker use based on the Registry for Ambulant Therapy With <jats:styled-content style=\"fixed-case\">RAS<\/jats:styled-content> Inhibitors in Hypertension Patients in Germany (3A). Of 14,986 patients included, 3772 patients had diabetes and 28.5% received aliskiren, 14.3% received angiotensin\u2010converting enzyme (<jats:styled-content style=\"fixed-case\">ACE<\/jats:styled-content>) inhibitors\/angiotensin receptor blockers (<jats:styled-content style=\"fixed-case\">ARB<\/jats:styled-content>s), 35.4% received aliskiren plus an <jats:styled-content style=\"fixed-case\">ACE<\/jats:styled-content> inhibitor\/<jats:styled-content style=\"fixed-case\">ARB,<\/jats:styled-content> and 10.5% received other drugs. Ambulatory blood pressure (<jats:styled-content style=\"fixed-case\">BP<\/jats:styled-content>) monitoring (baseline <jats:styled-content style=\"fixed-case\">BP<\/jats:styled-content> 148\u00b115.8\/84.0\u00b110.9 mm Hg) revealed stronger diastolic <jats:styled-content style=\"fixed-case\">BP<\/jats:styled-content> reduction for aliskiren plus <jats:styled-content style=\"fixed-case\">ACE<\/jats:styled-content> inhibitor\/<jats:styled-content style=\"fixed-case\">ARB<\/jats:styled-content> than aliskiren alone in the low (2.8\u00b10.5 vs 0.6\u00b10.6; <jats:italic>P<\/jats:italic>=.004) and intermediate (5.9\u00b10.5 vs 4.5\u00b10.5; <jats:italic>P<\/jats:italic>=.04) baseline <jats:styled-content style=\"fixed-case\">BP<\/jats:styled-content> groups. There was a lesser ambulatory <jats:styled-content style=\"fixed-case\">BP<\/jats:styled-content> reduction observed for patients receiving non\u2010<jats:styled-content style=\"fixed-case\">RAS<\/jats:styled-content> in the high baseline category for both systolic (12.5\u00b11.8 vs 17.1\u00b11.0; <jats:italic>P<\/jats:italic>=.02) and diastolic (6.9\u00b11.0 vs 9.8\u00b10.6; <jats:italic>P<\/jats:italic>=.01) <jats:styled-content style=\"fixed-case\">BP<\/jats:styled-content>. In patients with hypertension and type 2 diabetes, aliskiren was beneficial in lowering <jats:styled-content style=\"fixed-case\">BP<\/jats:styled-content>, with no observed increases in major adverse effects compared with <jats:styled-content style=\"fixed-case\">RAS<\/jats:styled-content>\u2010blocking therapy alone.<\/jats:p>","DOI":"10.1111\/jch.12828","type":"journal-article","created":{"date-parts":[[2016,4,20]],"date-time":"2016-04-20T09:32:27Z","timestamp":1461144747000},"page":"1045-1053","source":"Crossref","is-referenced-by-count":3,"title":["Benefits and Risks of Aliskiren Treatment in Patients With Type 2 Diabetes: Analyses of the 3A Registry"],"prefix":"10.1111","volume":"18","author":[{"given":"Iris","family":"Kistner","sequence":"first","affiliation":[{"name":"Nephrologie und Hypertensiologie Universit\u00e4tsklinikum Erlangen Erlangen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uwe","family":"Zeymer","sequence":"additional","affiliation":[{"name":"Institut f\u00fcr Herzinfarktforschung Ludwigshafen  Ludwigshafen Germany"},{"name":"Medizinische Klinik B Klinikum der Stadt Ludwigshafen Ludwigshafen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralf","family":"Dechend","sequence":"additional","affiliation":[{"name":"Medizinische Klinik mit Schwerpunkt Molekulare and Klinische Kardiologie Charit\u00e9 Universit\u00e4tsmedizin Berlin Berlin Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ina","family":"Hagedorn","sequence":"additional","affiliation":[{"name":"Clinical and Regulatory Affairs Novartis Pharma GmbH N\u00fcrnberg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Riemer","sequence":"additional","affiliation":[{"name":"Institut f\u00fcr Herzinfarktforschung Ludwigshafen  Ludwigshafen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Bramlage","sequence":"additional","affiliation":[{"name":"Institut f\u00fcr Pharmakologie and pr\u00e4ventive Medizin Mahlow Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Pittrow","sequence":"additional","affiliation":[{"name":"Institute for Clinical Pharmacology Medical Faculty Technical University Dresden Dresden Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jochen","family":"Senges","sequence":"additional","affiliation":[{"name":"Institut f\u00fcr Herzinfarktforschung Ludwigshafen  Ludwigshafen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roland E.","family":"Schmieder","sequence":"additional","affiliation":[{"name":"Nephrologie und Hypertensiologie Universit\u00e4tsklinikum Erlangen Erlangen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,4,20]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.284427"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht151"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.317.7160.703"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60108-1"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2840-11-1"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)62459-4"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000156466.02908.ED"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2007.01473.x"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000253780.36691.4f"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2006.11.032"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61124-6"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1208799"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.1954"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht342"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2012.02893.x"},{"key":"e_1_2_8_17_1","unstructured":"Verband der forschenden Arzneimittelhersteller (VfA).Registry of non\u2010interventional studies (NIS): 3A Register. Internet:http:\/\/www.vfa.de\/de\/arzneimittel-forschung\/datenbanken-zu-arzneimitteln\/nisdb\/nis-details\/_616. Accessed October 9 2011."},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-199715120-00018"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/jhh.2013.39"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000170138.56903.7a"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000160923.04524.5B"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/jch.12032"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.107.750745"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/jhh.2009.107"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/jhh.2010.38"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0708379"}],"container-title":["The Journal of Clinical Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjch.12828","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjch.12828","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jch.12828","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T14:37:45Z","timestamp":1695566265000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jch.12828"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,20]]},"references-count":25,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["10.1111\/jch.12828"],"URL":"https:\/\/doi.org\/10.1111\/jch.12828","archive":["Portico"],"relation":{},"ISSN":["1524-6175","1751-7176"],"issn-type":[{"value":"1524-6175","type":"print"},{"value":"1751-7176","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,20]]}}}